JACDEN PHARMA was invited by the Cuban Chamber of Commerce to visit Cuba from February 21-25, 2022, to meet with key stakeholders in the Cuban health sector. That visit resulted in JACDEN PHARMA securing MOUs with Farmacuba, Center for Genetic Engineering and Biotechnology (CIGB), Medical Technology manufacturer company (COMBIOMED), Center of Molecular Immunology (CIM), Finlay institute of vaccines (IFV), Ministry of Public Health (MINSAP), LABIOFARM, La Pradera International Center for Wellness and Center of Immunoassay(CIE).
The MOUs will see JACDEN PHARMA exploring the exclusive importation of medicines, vaccines, medical equipment, maintenance support for medical machines, manufacturing of medical equipment, medical services, and medical tourism in conjunction with Cuba in the Jamaican market. These arrangements have short-, medium- and long-term benefits for the Jamaican health sector, and will be valuable in Jamaica achieving the 2030 goals for health care in Jamaica.
JACDEN PHARMA began the exploration of a bilateral partner with BIOCUBAFARMA in March 2021. By this time, the Cuban group had made significant strides on the medical frontier in producing vaccines for SARS-COVID-19. BIOCUBAFHARMA had designed three vaccines SOBERANA, SOBERANA 2 and Abdala. BIOCUBAFARMMA was the only company in the Caribbean and Latin America to have made these strides in developing vaccines to stem the tide of the SARS-COVID-19 pandemic.
In April 2021, an MOU was signed between JACDEN PHARMA and BIOCUBAFARMA with the assistance of the then Cuban Ambassador Her Excellence, Inez Fernandez. Subsequent meetings between JACDEN PHARMA and BIOCUBAFARMA revealed many innovative products and services in health that would be beneficial to improving access and equity in the Jamaican health sector.